Clinical Data's Vital Diagnostics Division Executes Distribution Agreement with Canada's Inter Medico to Sell Excyte Line of ESR Analyzers.

NEWTON, Mass. -- Clinical Data Inc. (NASDAQ: CLDA) announced today that its Vital Diagnostics division has signed a distribution agreement with Inter Medico, located in Markham, Ontario, Canada, to sell the Excyte line of Automated Erythrocyte Sedimentation Rate (ESR) Analyzers.

Gus Gardner, President, Clinical Data Sales and Services, said, "Inter Medico is the first Canadian distributor to sell the Excyte ESR product line. Our opportunity to sell automated ESR analyzers in Canada is considerable as the majority of ESR tests performed in Canada today are done individually by manual methods. This agreement with Inter Medico allows Clinical Data to place the Excyte Automated ESR Analyzers in small to-large hospital laboratories and in all private laboratories. We are quite pleased to now be associated with Inter Medico because they have longstanding relationships with the most admired IVD manufacturers in the world and are the largest Canadian-owned distributor of in vitro diagnostics."

"Inter Medico is pleased to bring the Excyte ESR product line to our Canadian customers," said Dan Lichtman, President, Inter Medico. "This technology provides a new level of automation to our customers and extends the current value we offer Canadian laboratories."

The Excyte 10, Excyte M, and Excyte 40 analyzers have received the Health Canada Medical Device License from the Therapeutic Products Directorate (TPD). In addition, the licensing of the Excyte 20 Scan and Excyte M Scan are currently in process with the TPD.

About Inter Medico

Inter Medico, founded in 1979 by Dan Lichtman, is the largest Canadian-owned distributor of in vitro diagnostics. Inter Medico's products can be found in Canadian Hospitals, Reference Laboratories, Universities, and the Biopharmaceutical industry.

Exclusive strategic alliances with world-class manufacturers have allowed Inter Medico to consistently deliver Innovative Diagnostic Solutions that advance medicine and patient care. Inter Medico is also active in the continual pursuit and development of new diagnostic technologies and medical research endeavors. Our goal is to create uniquely tailored systems solutions to provide strong long-term customer value.

About Clinical Data, Inc.

Clinical Data, Inc., a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care, is organized under three worldwide divisions segmented by service offerings and varying client constituents: PGxHealth[TM]; Cogenics[TM]; and Vital Diagnostics[TM]. The Pharmacogenomics and Molecular Services[TM] division, Cogenics, consolidates operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc., Icoria, Inc., and Genome Express SA to provide a comprehensive range of molecular biology and pharmacogenomics services to pharmaceutical, biotech, academic, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. PGxHealth builds upon existing assets and know-how acquired from Genaissance Pharmaceuticals, Icoria, and Genome Express in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth develops, validates and commercializes novel Therapeutic Diagnostics[TM], in some instances in combination with new and existing therapeutics, to improve patient care. In addition, PGxHealth has a therapeutic drug candidate, vilazodone, currently in late stage clinical trials for the treatment of depression. Vital Diagnostics serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide. With a focus on the physician's office, hospital and small-to-medium sized laboratory segments and customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States. Clinical Data is headquartered in Newton, Mass. with operations in Texas, Connecticut, North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2006, and fiscal 2005, 2006, and 2007 quarterly reports on Forms 10-QSB and 10-Q.

Internet Website: www.clda.com